Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03022552 · ClinicalTrials.gov registry record

Heart Attack Research Program: Platelet Sub-Study (HARP)

A clinical trial of Myocardial Infarction, sponsored by NYU Langone Health.

Recruiting
Registry status
350
Enrollment target
1
Study location

NCT03022552: Recruiting study of Myocardial Infarction, sponsored by NYU Langone Health.

NCT03022552 is a study of Myocardial Infarction that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 350 participants, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03022552, a study of Myocardial Infarction, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
350 participants
Enrollment target
1
Study location

Study Summary

This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.

Conditions Studied

Myocardial Infarction

Study Locations (1)

New York

  • NYU Langone Medical Center - New York

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2020-07-01
Est. Completion 2027-06-30
NYU Langone Health

1,164 total trials

What NCT03022552 shows while recruiting

NCT03022552 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.

NCT03022552 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03022552 about?

NCT03022552 is a clinical study titled "Heart Attack Research Program: Platelet Sub-Study (HARP)". This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Cente...

What is the current status of trial NCT03022552?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2020-07-01. Estimated completion is 2027-06-30.

What conditions does trial NCT03022552 study?

This clinical trial studies the following conditions: Myocardial Infarction.

Who is sponsoring clinical trial NCT03022552?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03022552 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03022552's enrollment target sits among peer trials

350 35th of 64 higher than 30 of 64 other Myocardial Infarction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03022552

Source: ClinicalTrials.gov NCT03022552, the US trial registry maintained by the National Library of Medicine. NCT03022552 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.